Eric Sullivan Email

Chief Financial Officer . Convergent Therapeutics

Current Roles

Employees:
18
Revenue:
$1.4M
About
Convergent Therapeutics is a clinical-stage biotechnology company exploring the full potential of dual-targeted combination strategies to treat cancer. Convergent has developed a therapeutic platform that is capable of targeting validated and novel cancer antigens. Building on breakthrough research developed by Dr. Neil Bander at Weill Cornell Medicine, Convergent has demonstrated that dual targeting of surface cancer molecules like Prostate-Specific Membrane Antigen (PSMA) improves antitumor efficacy. By leveraging targeting agents with different bio-distributions, such as monoclonal antibodies and ligands, supra-additive therapeutic doses are delivered to tumor cells without additive toxicity to the patient.
Convergent Therapeutics Address
1 Broadway 14th Floor
Cambridge, MA
Convergent Therapeutics Email
Convergent Therapeutics Phone Numbers
631-215-3897

Past Companies

Convergent Therapeutics, Inc.Chief Financial Officer
Chimeric TherapeuticsBoard of Directors, Chair of Audit & Risk Committee, Member of Remuneration & Nomination Committee
TCR² Therapeutics Inc. (TCR² was acquired by Adaptimmune Therapeutics on 6/1/23)Chief Financial Officer

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.